COAG - Hemab Therapeutics Holdings, Inc. Common Stock Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

COAG

HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK

NASDAQ

$44.84

▼ DOWN 9.40% (-4.65)

KEY STATISTICS

Market Cap$2.09 B

52w High$55.42

52w Low$23.00

Dividend Yield—

Frequency—

P/E-1.87

Volume260.08K

Shares Out.46.71M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Benny Sorensen

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 1, 2026

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$64.00

Target Low$36.00

Target Median$50.00

Target Consensus$51.40

PRICE

$44.84 ▼ DOWN 9.40% (−$4.65)

About Hemab Therapeutics Holdings, Inc. Common Stock

https://www.hemab.com ↗

Hemab Therapeutics is a clinical-stage biotech developing innovative therapies for blood coagulation disorders, with products in Phase 1/2 and Phase 2 trials, based in Cambridge, MA, serving the US and Denmark.

INDUSTRY

Biotechnology

A PRODUCT HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK IS KNOWN FOR

sutacimig (HMB-001)

Sutacimig, Hemab's breakthrough bispecific antibody in clinical trials, is a subcutaneously administered, first-in-class preventive treatment for Glanzmann thrombasthenia and Factor VII deficiency.